Alimera Sciences, Inc. (NASDAQ:ALIM) is scheduled to be releasing its earnings data after the market closes on Tuesday, October 31st. Analysts expect Alimera Sciences to post earnings of ($0.05) per share for the quarter.

Alimera Sciences (NASDAQ:ALIM) last issued its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The firm had revenue of $10.40 million during the quarter, compared to analyst estimates of $10.20 million. The business’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.17) earnings per share. On average, analysts expect Alimera Sciences to post $-0.22 EPS for the current fiscal year and $-0.03 EPS for the next fiscal year.

Shares of Alimera Sciences, Inc. (NASDAQ:ALIM) opened at 1.26 on Tuesday. The stock has a 50 day moving average price of $1.36 and a 200 day moving average price of $1.42. The firm’s market capitalization is $87.00 million. Alimera Sciences, Inc. has a 52 week low of $1.03 and a 52 week high of $1.72.

ILLEGAL ACTIVITY NOTICE: This news story was reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/10/24/alimera-sciences-inc-alim-set-to-announce-earnings-on-tuesday.html.

A number of research firms recently issued reports on ALIM. HC Wainwright set a $5.00 price target on shares of Alimera Sciences and gave the stock a “buy” rating in a research note on Tuesday, July 11th. Cowen and Company reissued a “buy” rating and issued a $3.00 price target on shares of Alimera Sciences in a research note on Tuesday, July 11th. Zacks Investment Research downgraded shares of Alimera Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 13th. Finally, ValuEngine raised shares of Alimera Sciences from a “strong sell” rating to a “sell” rating in a research note on Friday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. Alimera Sciences presently has an average rating of “Hold” and an average target price of $3.38.

Alimera Sciences Company Profile

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Earnings History for Alimera Sciences (NASDAQ:ALIM)

Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.